Trevor Baglin
Private Equity Investor chez Medicxi Ventures (Jersey) Ltd.
Postes actifs de Trevor Baglin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Medicxi Ventures (Jersey) Ltd.
 Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Private Equity Investor | 01/01/2017 | - |
Historique de carrière de Trevor Baglin
Anciens postes connus de Trevor Baglin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Z Factor Ltd.
 Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Corporate Officer/Principal | - | - |
SuperX Ltd.
 SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Directeur/Membre du Conseil | 10/11/2015 | - |
| Directeur Technique/Scientifique/R&D | 10/11/2015 | - | |
| Fondateur | 10/11/2015 | - | |
XO1 Ltd.
 XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Fondateur | - | - |
ApcinteX Ltd.
 ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Fondateur | 16/06/2014 | - |
Formation de Trevor Baglin
| University of Birmingham | Doctorate Degree |
| University of Cambridge | Graduate Degree |
| The University of Manchester | Undergraduate Degree |
Statistiques
Internationale
| Royaume-Uni | 8 |
| Israël | 2 |
Opérationnelle
| Founder | 3 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 4 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 5 |
|---|---|
ApcinteX Ltd.
ApcinteX Ltd. BiotechnologyHealth Technology ApcinteX Ltd. develops and markets anticoagulant APC pathway to treat haemophilia. The company is headquartered in London, the United Kingdom. | Health Technology |
SuperX Ltd.
SuperX Ltd. BiotechnologyHealth Technology SuperX Ltd. operates as a biopharmaceutical firm. It develops antibodies with anticoagulant properties. The company was founded by Trevor Baglin, David Grainger, and Jim Huntington and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
XO1 Ltd.
XO1 Ltd. Medical/Nursing ServicesHealth Services XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom. | Health Services |
Z Factor Ltd.
Z Factor Ltd. BiotechnologyHealth Technology Z Factor Ltd. operates as a drug discovery company. It identifies and develops therapeutic agents to treat alpha-1-antitrypsin deficiency. The company was founded by James Huntington in 2015 and is headquartered in Babraham, the united Kingdom. | Health Technology |
- Bourse
- Insiders
- Trevor Baglin
- Expérience